COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02287428
Recruitment Status : Active, not recruiting
First Posted : November 10, 2014
Last Update Posted : May 29, 2019
The Ben & Catherine Ivy Foundation
Accelerate Brain Cancer Cure
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
David Reardon, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2021